Anavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimer's Disease

Anavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimer's Disease#Anavex #Life #Sciences #Announces #Positive #4Years #Oral #Blarcamesine #Results #Phase #IIbIII #OpenLabel #Extension #Trial #Early #Alzheimer039s #Disease